Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000421106 | SCV000523926 | benign | not specified | 2016-06-30 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Labcorp Genetics |
RCV000459668 | SCV000554242 | benign | Developmental and epileptic encephalopathy, 36 | 2024-01-30 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000421106 | SCV000612316 | benign | not specified | 2017-06-28 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000459668 | SCV002524944 | benign | Developmental and epileptic encephalopathy, 36 | 2021-12-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002436284 | SCV002752843 | benign | Inborn genetic diseases | 2017-07-21 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV000459668 | SCV002797508 | likely benign | Developmental and epileptic encephalopathy, 36 | 2021-10-30 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003942373 | SCV004761788 | benign | ALG13-related disorder | 2020-01-02 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |